Advancing non-small cell lung cancer treatment: the power of combination immunotherapies

被引:0
|
作者
Wu, Yuanlin [1 ]
Yu, Guangmao [1 ]
Jin, Ketao [2 ]
Qian, Jun [3 ]
机构
[1] Shaoxing Peoples Hosp, Dept Thorac Surg, Shaoxing, Zhejiang, Peoples R China
[2] Westlake Univ, Affiliated Hangzhou Peoples Hosp 1, Sch Med, Dept Gastrointestinal Colorectal & Anal Surg, Hangzhou, Zhejiang, Peoples R China
[3] Wenzhou Med Univ, Xinchang Peoples Hosp, Affiliated Xinchang Hosp, Dept Colorectal Surg, Xinchang, Zhejiang, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2024年 / 15卷
关键词
non-small cell lung cancer; immunotherapy; combination therapy; cancer vaccines; tumor microenvironment; TUMOR-INFILTRATING LYMPHOCYTES; IMMUNE-CHECKPOINT INHIBITOR; TYROSINE KINASE INHIBITORS; REGULATORY T-CELLS; PD-L1; EXPRESSION; ADVANCED NSCLC; OPEN-LABEL; PHASE-III; 1ST-LINE NIVOLUMAB; TARGETED THERAPIES;
D O I
10.3389/fimmu.2024.1349502
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Non-small cell lung cancer (NSCLC) remains an unsolved challenge in oncology, signifying a substantial global health burden. While considerable progress has been made in recent years through the emergence of immunotherapy modalities, such as immune checkpoint inhibitors (ICIs), monotherapies often yield limited clinical outcomes. The rationale behind combining various immunotherapeutic or other anticancer agents, the mechanistic underpinnings, and the clinical evidence supporting their utilization is crucial in NSCLC therapy. Regarding the synergistic potential of combination immunotherapies, this study aims to provide insights to help the landscape of NSCLC treatment and improve clinical outcomes. In addition, this review article discusses the challenges and considerations of combination regimens, including toxicity management and patient selection.
引用
收藏
页数:31
相关论文
共 50 条
  • [31] Treatment of non-small cell lung cancer (NSCLC)
    Zarogoulidis, Konstantinos
    Zarogoulidis, Paul
    Darwiche, Kaid
    Boutsikou, Efimia
    Machairiotis, Nikolaos
    Tsakiridis, Kosmas
    Katsikogiannis, Nikolaos
    Kougioumtzi, Ioanna
    Karapantzos, Ilias
    Huang, Haidong
    Spyratos, Dionysios
    JOURNAL OF THORACIC DISEASE, 2013, 5 : S389 - S396
  • [32] The treatment of advanced non-small cell lung cancer
    Spiro, SG
    Silvestri, GA
    CURRENT OPINION IN PULMONARY MEDICINE, 2005, 11 (04) : 287 - 291
  • [33] Radiation Treatment of Non-Small Cell Lung Cancer
    Zeng, Jing
    Rengan, Ramesh
    SEMINARS IN RADIATION ONCOLOGY, 2021, 31 (02) : 95 - 96
  • [34] Aptamers in Non-Small Cell Lung Cancer Treatment
    Wieleba, Irena
    Wojas-Krawczyk, Kamila
    Krawczyk, Pawel
    MOLECULES, 2020, 25 (14):
  • [35] Afatinib for the treatment of non-small cell lung cancer
    Biello, Federica
    Maggioni, Claudia
    Rijavec, Erika
    Genova, Carlo
    Barletta, Giulia
    Gualco, Elisa
    Truini, Anna
    Coco, Simona
    Dal Bello, Maria Giovanna
    Vanni, Irene
    Alama, Angela
    Boccardo, Francesco
    Grossi, Francesco
    EXPERT OPINION ON ORPHAN DRUGS, 2015, 3 (11): : 1357 - 1364
  • [36] Targeted treatment of non-small cell lung cancer
    Scheffler, Matthias
    Michels, Sebastian
    Nogova, Lucia
    INNERE MEDIZIN, 2022, 63 (07): : 700 - 708
  • [37] Current treatment of non-small cell lung cancer
    Tonato, M
    TUMORI JOURNAL, 2002, : S7 - S8
  • [38] Personalized treatment in non-small cell lung cancer
    Delia Campos-Parra, Alma
    Cruz-Rico, Graciela
    Arrieta, Oscar
    REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION, 2012, 64 (04): : 377 - 386
  • [39] Pembrolizumab for the treatment of non-small cell lung cancer
    Lim, Sung Hee
    Sun, Jong-Mu
    Lee, Se-Hoon
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2016, 16 (03) : 397 - 406
  • [40] Sintilimab for the treatment of non-small cell lung cancer
    Zhang, Lin
    Lin, Weihao
    Tan, Fengwei
    Li, Ning
    Xue, Qi
    Gao, Shugeng
    Gao, Yibo
    He, Jie
    BIOMARKER RESEARCH, 2022, 10 (01)